{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:23:15Z","timestamp":1792790595633,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","award":["22234"],"award-info":[{"award-number":["22234"]}],"id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Federal Government, Department of Education; Tour de Cure","id":[{"id":"https:\/\/ror.org\/056q84j13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a high-risk hematological disease constituting ~20% of acute leukemias. To date, the only subtype recognized by the World Health Organization\u2019s International Consensus Classification is early T-cell precursor ALL. To improve clinical outcomes, several studies have investigated and defined T-ALL genomic subtypes within cohorts of varied ages and geographical locations. These studies have also utilized differing analysis methods including whole transcriptome, exome, or genome sequencing as well as immunophenotyping and cytogenetic testing. As a result, there are significant differences in reported subtypes as well as the frequency at which each occurs. The reported clinical outcomes for specific genomic alterations also depend on patient demographics and treatment protocols. This review synthesizes the data from four T-ALL genomic landscape studies establishing consensus and highlighting differences, details clinical outcomes for the most common genomic alterations observed in T-ALL patients, and proposes novel avenues for future investigation and treatment.<\/jats:p>","DOI":"10.1038\/s41375-025-02599-2","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:23:47Z","timestamp":1744885427000},"page":"1294-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-7243","authenticated-orcid":false,"given":"Maxim","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-333X","authenticated-orcid":false,"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-7602","authenticated-orcid":false,"given":"Laura N.","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","volume":"120","author":"CH Pui","year":"2012","unstructured":"Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric ALL: where are we going and how do we get there?. Blood. 2012;120:1165\u201374.","journal-title":"Blood"},{"key":"2599_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.","journal-title":"Blood Cancer J"},{"key":"2599_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2599_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjh.17879","volume":"197","author":"DTO Yeung","year":"2022","unstructured":"Yeung DTO, Osborn MP, White DL. B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. British J Haematol. 2022;197:13\u201327.","journal-title":"British J Haematol"},{"key":"2599_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","volume":"482","author":"AS Duffield","year":"2023","unstructured":"Duffield AS, Mullighan CG, Borowitz MJ. International consensus classification of acute lymphoblastic leukemia\/lymphoma. Virchows Arch. 2023;482:11\u201326.","journal-title":"Virchows Arch"},{"key":"2599_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/genes12081118","volume":"12","author":"V Bardelli","year":"2021","unstructured":"Bardelli V, Arniani S, Pierini V, Di Giacomo D, Pierini T, Gorello P, et al. T-Cell ALL: biomarkers and their clinical usefulness. Genes. 2021;12:1118.","journal-title":"Genes"},{"key":"2599_CR7","doi-asserted-by":"crossref","unstructured":"Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. J Clin Oncol. 2009;27:4352\u20136.","DOI":"10.3324\/haematol.2008.005272"},{"key":"2599_CR8","doi-asserted-by":"crossref","unstructured":"Hayette S, Tigaud I, Maguer-Satta V, Bartholin L, Thomas X, Charrin C, et al. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood. 2002;99:4647-9.","DOI":"10.1182\/blood-2002-03-0717"},{"key":"2599_CR9","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1182\/blood-2006-04-014514","volume":"108","author":"T Burmeister","year":"2006","unstructured":"Burmeister T, Gokbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S. NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood. 2006;108:3556\u20139.","journal-title":"Blood"},{"key":"2599_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41416-019-0647-7","volume":"122","author":"P Tavakoli Shirazi","year":"2020","unstructured":"Tavakoli Shirazi P, Eadie LN, Heatley SL, Hughes TP, Yeung DT, White DL. The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL. British J Cancer. 2020;122:455\u201364.","journal-title":"British J Cancer"},{"key":"2599_CR11","doi-asserted-by":"crossref","unstructured":"Truong TH, Jinca C, Mann G, Arghirescu S, Buechner J, Merli P, et al. Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy. Front Pediatr. 2021;9:782785.","DOI":"10.3389\/fped.2021.782785"},{"key":"2599_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. New Engl J Med. 2017;376:836\u201347.","journal-title":"New Engl J Med"},{"key":"2599_CR13","doi-asserted-by":"publisher","first-page":"e034629","DOI":"10.1136\/bmjopen-2019-034629","volume":"10","author":"P George","year":"2020","unstructured":"George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, et al. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020;10:e034629.","journal-title":"BMJ Open"},{"key":"2599_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120787119","volume":"119","author":"Y-T Dai","year":"2022","unstructured":"Dai Y-T, Zhang F, Fang H, Li J-F, Lu G, Jiang L, et al. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proceedings Natl Acad Sci. 2022;119:e2120787119.","journal-title":"Proceedings Natl Acad Sci"},{"key":"2599_CR15","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage ALL. Nature Genet. 2017;49:1211\u20138.","journal-title":"Nature Genet."},{"key":"2599_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41375-022-01743-6","volume":"37","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Walter W, Haferlach C, M\u00fcller H, Fuhrmann I, M\u00fcller M-L, et al. How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing. Leukemia. 2023;37:217\u201321.","journal-title":"Leukemia"},{"key":"2599_CR17","doi-asserted-by":"crossref","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE, Elsayed A, Kimura S, Benini F, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukemia. Nature. 2024;632:1082\u201391.","DOI":"10.1038\/s41586-024-07807-0"},{"key":"2599_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6246","volume":"11","author":"RA Habets","year":"2019","unstructured":"Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Science Transl Med. 2019;11:eaau6246.","journal-title":"Science Transl Med"},{"key":"2599_CR19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","volume":"30","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I Study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal Clin Oncol. 2012;30:2348\u201353.","journal-title":"Journal Clin Oncol"},{"key":"2599_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncol. 2015;137:216\u201322.","journal-title":"Gynecologic Oncol"},{"key":"2599_CR21","doi-asserted-by":"crossref","unstructured":"Edwards A, Brennan K. Notch Signalling in Breast Development and Cancer. Front Cell Dev Biol. 2021;9:1\u201324.","DOI":"10.3389\/fcell.2021.692173"},{"key":"2599_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","volume":"7","author":"S Shimony","year":"2023","unstructured":"Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, et al. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia. Blood Adv. 2023;7:1092\u2013102.","journal-title":"Blood Adv"},{"key":"2599_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen S-J, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nature Rev Dis Prim. 2024;10:41.","journal-title":"Nature Rev Dis Prim"},{"key":"2599_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.2023022154","volume":"144","author":"E Balducci","year":"2024","unstructured":"Balducci E, Simonin M, Duployez N, Steiml\u00e9 T, Dourthe M-E, Villarese P, et al. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. Blood. 2024;144:988\u20131000.","journal-title":"Blood"},{"key":"2599_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34:682\u201396.","journal-title":"Leukemia"},{"key":"2599_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1521-6926(03)00086-0","volume":"16","author":"T Szczepa\u0144ski","year":"2003","unstructured":"Szczepa\u0144ski T, van der Velden VHJ, van Dongen JJM. Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol. 2003;16:561\u201382.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2599_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol."},{"key":"2599_CR28","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863\u20139.","journal-title":"Blood"},{"key":"2599_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","volume":"156","author":"T Inukai","year":"2012","unstructured":"Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15. British J Haematol. 2012;156:358\u201365.","journal-title":"British J Haematol"},{"key":"2599_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","volume":"6","author":"M Ma","year":"2012","unstructured":"Ma M, Wang X, Tang J, Xue H, Chen J, Pan C, et al. Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Frontiers Med. 2012;6:416\u201320.","journal-title":"Frontiers Med"},{"key":"2599_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.26144","volume":"96","author":"K Morita","year":"2021","unstructured":"Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, et al. Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. American J Hematol. 2021;96:589\u201398.","journal-title":"American J Hematol"},{"key":"2599_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28719","volume":"68","author":"MA Burns","year":"2021","unstructured":"Burns MA, Place AE, Stevenson KE, Guti\u00e9rrez A, Forrest S, Pikman Y, et al. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatric Blood Cancer. 2021;68:e28719.","journal-title":"Pediatric Blood Cancer"},{"key":"2599_CR33","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s00432-021-03551-4","volume":"147","author":"X Liu","year":"2021","unstructured":"Liu X, Zou Y, Zhang L, Chen X, Yang W, Guo Y, et al. Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China. Journal Cancer Res Clin Oncol. 2021;147:2775\u201388.","journal-title":"Journal Cancer Res Clin Oncol"},{"key":"2599_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. British J Haematol. 2014;166:421\u20134.","journal-title":"British J Haematol"},{"key":"2599_CR35","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1038\/bcj.2011.49","volume":"2","author":"M Neumann","year":"2012","unstructured":"Neumann M, Heesch S, G\u00f6kbuget N, Schwartz S, Schlee C, Benlasfer O, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012;2:e55\u2013e.","journal-title":"Blood Cancer J"},{"key":"2599_CR36","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","volume":"35","author":"J Bond","year":"2017","unstructured":"Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response\u2013based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. Journal Clin Oncol. 2017;35:2683\u201391.","journal-title":"Journal Clin Oncol"},{"key":"2599_CR37","doi-asserted-by":"crossref","unstructured":"Zhang Y, Qian JJ, Zhou YL, Huang X, Li JH, Li XY, et al. Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia. Front Oncol. 2020;10:1423.","DOI":"10.3389\/fonc.2020.01423"},{"key":"2599_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s12185-023-03546-6","volume":"117","author":"Y Onishi","year":"2023","unstructured":"Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S, et al. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia\/lymphoma (ALL) and non-ETP T-ALL. International J Hematol. 2023;117:738\u201347.","journal-title":"International J Hematol"},{"key":"2599_CR39","volume":"71","author":"J De Bie","year":"2023","unstructured":"De Bie J, Quessada J, Tueur G, Lefebvre C, Luquet I, Toujani S, et al. Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH). Current Res Transl Med. 2023;71:103431.","journal-title":"Current Res Transl Med"},{"key":"2599_CR40","doi-asserted-by":"crossref","unstructured":"Khan AU, Qu R, Ouyang J, Dai J. Role of Nucleoporins and Transport Receptors in Cell Differentiation. Front Physiol. 2020;11:239.","DOI":"10.3389\/fphys.2020.00239"},{"key":"2599_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2013.088674","volume":"99","author":"K De Keersmaecker","year":"2014","unstructured":"De Keersmaecker K, Micha\u00ebl P, Luk C, Tiziana G, Roel V, de Joyce Op B, et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica. 2014;99:85\u201393.","journal-title":"Haematologica"},{"key":"2599_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00613-9","volume":"12","author":"T Steiml\u00e9","year":"2022","unstructured":"Steiml\u00e9 T, Dourthe M-E, Alcantara M, Touzart A, Simonin M, Mondesir J, et al. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Blood Cancer J. 2022;12:14.","journal-title":"Blood Cancer J"},{"key":"2599_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/hematology.2022000357","volume":"2022","author":"TH Tran","year":"2022","unstructured":"Tran TH, Tasian SK. Clinical screening for Ph-like ALL and the developing role of TKIs. Hematology. 2022;2022:594\u2013602.","journal-title":"Hematology"},{"key":"2599_CR44","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.2021014689","volume":"139","author":"DT Yeung","year":"2022","unstructured":"Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022;139:3474\u20139.","journal-title":"Blood"},{"key":"2599_CR45","doi-asserted-by":"crossref","unstructured":"Eadie LN, Lagonik E, Page EC, Schutz CE, Heatley SL, McClure BJ, et al. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood. 2024;144:1022\u20136.","DOI":"10.1182\/blood.2024024776"},{"key":"2599_CR46","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1182\/blood-2023-184647","volume":"142","author":"LN Eadie","year":"2023","unstructured":"Eadie LN, Schutz CE, Page EC, Conlin TS, Heatley SL, Lagonik E, et al. Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. Blood. 2023;142:1602.","journal-title":"Blood"},{"key":"2599_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2008-07-166801","volume":"113","author":"S Sulong","year":"2009","unstructured":"Sulong S, Moorman AV, Irving JAE, Strefford JC, Konn ZJ, Case MC, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100\u20137.","journal-title":"Blood"},{"key":"2599_CR48","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/diagnostics13091589","volume":"13","author":"M Ampatzidou","year":"2023","unstructured":"Ampatzidou M, Papadhimitriou SI, Paisiou A, Paterakis G, Tzanoudaki M, Papadakis V, et al. The prognostic effect of CDKN2A\/2B gene deletions in pediatric acute lymphoblastic leukemia (ALL): Independent prognostic significance in BFM-based protocols. Diagnostics. 2023;13:1589.","journal-title":"Diagnostics"},{"key":"2599_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","volume":"51","author":"W Zhang","year":"2019","unstructured":"Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Annals Med. 2019;51:28\u201340.","journal-title":"Annals Med"},{"key":"2599_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/08880018.2016.1251518","volume":"33","author":"P Carrasco Salas","year":"2016","unstructured":"Carrasco Salas P, Fern\u00e1ndez L, Vela M, Bueno D, Gonz\u00e1lez B, Valent\u00edn J, et al. The role of CDKN2A\/B deletions in pediatric acute lymphoblastic leukemia. Pediatric Hematol Oncol. 2016;33:415\u201322.","journal-title":"Pediatric Hematol Oncol"},{"key":"2599_CR51","doi-asserted-by":"publisher","first-page":"878098","DOI":"10.3389\/fonc.2022.878098","volume":"12","author":"J Feng","year":"2022","unstructured":"Feng J, Guo Y, Yang W, Zou Y, Zhang L, Chen Y, et al. Childhood acute b-lineage lymphoblastic leukemia with CDKN2A\/B deletion is a distinct entity with adverse genetic features and poor clinical outcomes. Frontiers Oncol. 2022;12:878098.","journal-title":"Frontiers Oncol"},{"key":"2599_CR52","doi-asserted-by":"publisher","first-page":"e27001","DOI":"10.1002\/pbc.27001","volume":"65","author":"M Agarwal","year":"2018","unstructured":"Agarwal M, Bakhshi S, Dwivedi SN, Kabra M, Shukla R, Seth R. Cyclin dependent kinase inhibitor 2A\/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatric Blood Cancer. 2018;65:e27001.","journal-title":"Pediatric Blood Cancer"},{"key":"2599_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer cell. 2002;1:75\u201387.","journal-title":"Cancer cell"},{"key":"2599_CR54","doi-asserted-by":"crossref","unstructured":"Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038\u201344.","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038"},{"key":"2599_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0352-x","volume":"51","author":"W Jang","year":"2019","unstructured":"Jang W, Park J, Kwon A, Choi H, Kim J, Lee GD, et al. CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia. Experimental Mol Med. 2019;51:1\u201315.","journal-title":"Experimental Mol Med"},{"key":"2599_CR56","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.26069","volume":"96","author":"H-P Wang","year":"2021","unstructured":"Wang H-P, Zhou Y-L, Huang X, Zhang Y, Qian J-J, Li J-H, et al. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. American J Hematol. 2021;96:312\u20139.","journal-title":"American J Hematol"},{"key":"2599_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nature Rev Cancer. 2017;17:93\u2013115.","journal-title":"Nature Rev Cancer"},{"key":"2599_CR58","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","volume":"107","author":"KL Bride","year":"2021","unstructured":"Bride KL, Hu H, Tikhonova A, Fuller TJ, Vincent TL, Shraim R, et al. Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia. Haematologica. 2021;107:1746\u201357.","journal-title":"Haematologica"},{"key":"2599_CR59","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood-2006-12-064683","volume":"110","author":"E Clappier","year":"2007","unstructured":"Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela J-M, Dik WA, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110:1251\u201361.","journal-title":"Blood"},{"key":"2599_CR60","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nature Genet. 2022;54:1376\u201389.","journal-title":"Nature Genet"},{"key":"2599_CR61","doi-asserted-by":"crossref","unstructured":"Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496\u2013510.","DOI":"10.1038\/sj.leu.2404302"},{"key":"2599_CR62","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2009.177","volume":"23","author":"R Ono","year":"2009","unstructured":"Ono R, Kumagai H, Nakajima H, Hishiya A, Taki T, Horikawa K, et al. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia. 2009;23:2197\u2013209.","journal-title":"Leukemia"},{"key":"2599_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3343\/alm.2016.36.2.85","volume":"36","author":"R Marschalek","year":"2016","unstructured":"Marschalek R. Systematic classification of mixed-lineage leukemia fusion partners predicts additional cancer pathways. Ann Lab Med. 2016;36:85\u2013100.","journal-title":"Ann Lab Med"},{"key":"2599_CR64","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.exphem.2015.05.012","volume":"43","author":"C-W Chen","year":"2015","unstructured":"Chen C-W, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015;43:673\u201384.","journal-title":"Exp Hematol"},{"key":"2599_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/gcc.22666","volume":"57","author":"JF Peterson","year":"2018","unstructured":"Peterson JF, Baughn LB, Pearce KE, Williamson CM, Benevides Demasi JC, Olson RM, et al. KMT2A (MLL) rearrangements observed in pediatric\/young adult T-lymphoblastic leukemia\/lymphoma: A 10-year review from a single cytogenetic laboratory. Genes, Chromosomes Cancer. 2018;57:541\u20136.","journal-title":"Genes, Chromosomes Cancer"},{"key":"2599_CR66","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.canlet.2019.11.005","volume":"469","author":"MO Forgione","year":"2020","unstructured":"Forgione MO, McClure BJ, Eadie LN, Yeung DT, White DL. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett. 2020;469:410\u20138.","journal-title":"Cancer Lett"},{"key":"2599_CR67","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"2599_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10378-w","volume":"22","author":"K-y Qiu","year":"2022","unstructured":"Qiu K-y, Zhou D-h, Liao X-y, Huang K, Li Y, Xu H-g, et al. Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study. BMC Cancer. 2022;22:1257.","journal-title":"BMC Cancer"},{"key":"2599_CR69","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, et al. High frequency and poor outcome of Philadelphia chromosome\u2013like acute lymphoblastic leukemia in adults. Journal Clin Oncol. 2017;35:394\u2013401.","journal-title":"Journal Clin Oncol"},{"key":"2599_CR70","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"2599_CR71","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.3390\/ijms20122929","volume":"20","author":"N Coccaro","year":"2019","unstructured":"Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Next-generation sequencing in acute lymphoblastic leukemia. International J Mol Sci. 2019;20:2929.","journal-title":"International J Mol Sci"},{"key":"2599_CR72","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.3390\/cancers14133236","volume":"14","author":"S Matos","year":"2022","unstructured":"Matos S, Bernardo P, Esteves S, Botelho de Sousa A, Lemos M, Ribeiro P, et al. Screening a targeted panel of genes by next-generation sequencing improves risk stratification in real world patients with acute myeloid leukemia. Cancers. 2022;14:3236.","journal-title":"Cancers"},{"key":"2599_CR73","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","volume":"131","author":"A Petit","year":"2018","unstructured":"Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela J-M, Grardel N, et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131:289\u2013300.","journal-title":"Blood"},{"key":"2599_CR74","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41375-022-01799-4","volume":"37","author":"C Schwab","year":"2023","unstructured":"Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia. 2023;37:529\u201338.","journal-title":"Leukemia"},{"key":"2599_CR75","doi-asserted-by":"crossref","unstructured":"Yeung DT, Eadie LN, Rehn J, Heatley SL, McClure BJ, Page EC, et al. Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol. Blood Neoplasia. 2025;2:100041.","DOI":"10.1016\/j.bneo.2024.100041"},{"key":"2599_CR76","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2023023754","volume":"144","author":"M Simonin","year":"2024","unstructured":"Simonin M, Vasseur L, Lenglin\u00e9 E, Lhermitte L, Cabannes-Hamy A, Balsat M, et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. Blood. 2024;144:1570\u201380.","journal-title":"Blood"},{"key":"2599_CR77","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/biology12070997","volume":"12","author":"H Satam","year":"2023","unstructured":"Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-generation sequencing technology: current trends and advancements. Biology. 2023;12:997.","journal-title":"Biology"},{"key":"2599_CR78","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.3390\/ijms23094574","volume":"23","author":"V-P M\u00e4kinen","year":"2022","unstructured":"M\u00e4kinen V-P, Rehn J, Breen J, Yeung D, White DL. Multi-cohort transcriptomic subtyping of B-cell acute lymphoblastic leukemia. International J Mol Sci. 2022;23:4574.","journal-title":"International J Mol Sci"},{"key":"2599_CR79","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Abdelali RB, Lambert J, Beldjord K, Lenglin\u00e9 E, et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN\u2013based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. Journal Clin Oncol. 2013;31:4333\u201342.","journal-title":"Journal Clin Oncol"},{"key":"2599_CR80","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3324\/haematol.2011.059030","volume":"97","author":"L Zuurbier","year":"2012","unstructured":"Zuurbier L, Petricoin EF, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JGCAM, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97:1405\u201313.","journal-title":"Haematologica"},{"key":"2599_CR81","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","volume":"27","author":"MR Mansour","year":"2009","unstructured":"Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with t-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol. Journal Clin Oncol. 2009;27:4352\u20136.","journal-title":"Journal Clin Oncol"},{"key":"2599_CR82","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood-2013-08-521518","volume":"123","author":"R Ben Abdelali","year":"2014","unstructured":"Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A, et al. SET-NUP214 is a recurrent \u03b3\u03b4 lineage-specific fusion transcript associated with corticosteroid\/chemotherapy resistance in adult T-ALL. Blood. 2014;123:1860\u20133.","journal-title":"Blood"},{"key":"2599_CR83","first-page":"4668","volume":"111","author":"P Van Vlierberghe","year":"2008","unstructured":"Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood, J Am Soc Hematol. 2008;111:4668\u201380.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2599_CR84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2162-3619-1-22","volume":"1","author":"X Huang","year":"2012","unstructured":"Huang X, Du X, Li Y. The role of BCL11B in hematological malignancy. Experimental Hematol Oncol. 2012;1:22.","journal-title":"Experimental Hematol Oncol"},{"key":"2599_CR85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human t cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science"},{"key":"2599_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-014-0051-y","volume":"7","author":"I Bartram","year":"2014","unstructured":"Bartram I, G\u00f6kbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, et al. Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. Journal Hematol Oncol. 2014;7:51.","journal-title":"Journal Hematol Oncol"},{"key":"2599_CR87","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1084\/jem.20112239","volume":"208","author":"P Van Vlierberghe","year":"2011","unstructured":"Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, et al. ETV6 mutations in early immature human T cell leukemias. Journal Exp Med. 2011;208:2571\u20139.","journal-title":"Journal Exp Med"},{"key":"2599_CR88","doi-asserted-by":"publisher","first-page":"e53190","DOI":"10.1371\/journal.pone.0053190","volume":"8","author":"M Neumann","year":"2013","unstructured":"Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Farhadi Sartangi N, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One. 2013;8:e53190.","journal-title":"PLoS One"},{"key":"2599_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-560","volume":"10","author":"C Schult","year":"2010","unstructured":"Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer. 2010;10:560.","journal-title":"BMC Cancer"},{"key":"2599_CR90","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","volume":"104","author":"B Ali","year":"2019","unstructured":"Ali B, Myriam L, Giorgia B, Azedine D, Jakob P, Gerard S, et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. Haematologica. 2019;104:e398\u2013e401.","journal-title":"Haematologica"},{"key":"2599_CR91","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"2599_CR92","doi-asserted-by":"crossref","unstructured":"Champhekar A, Damle SS, Freedman G, Carotta S, Nutt SL, Rothenberg EV. Regulation of early T-lineage gene expression and developmental progression by the progenitor cell transcription factor PU.1. Genes Dev. 2015;29:832\u201348.","DOI":"10.1101\/gad.259879.115"},{"key":"2599_CR93","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/leu.2010.104","volume":"24","author":"P Burda","year":"2010","unstructured":"Burda P, Laslo P, Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia. 2010;24:1249\u201357.","journal-title":"Leukemia"},{"key":"2599_CR94","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.3900","volume":"49","author":"M Seki","year":"2017","unstructured":"Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nature Genet. 2017;49:1274\u201381.","journal-title":"Nature Genet"},{"key":"2599_CR95","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1203\/00006450-199710000-00001","volume":"42","author":"M Mark","year":"1997","unstructured":"Mark M, Rijli FM, Chambon P. Homeobox genes in embryogenesis and pathogenesis. Pediatric Res. 1997;42:421\u20139.","journal-title":"Pediatric Res"},{"key":"2599_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24044-5","volume":"12","author":"L Yang","year":"2021","unstructured":"Yang L, Chen F, Zhu H, Chen Y, Dong B, Shi M, et al. 3D genome alterations associated with dysregulated HOXA13 expression in high-risk T-lineage acute lymphoblastic leukemia. Nat Commun. 2021;12:3708.","journal-title":"Nat Commun"},{"key":"2599_CR97","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/leu.2008.52","volume":"22","author":"U Baak","year":"2008","unstructured":"Baak U, G\u00f6kbuget N, Orawa H, Schwartz S, Hoelzer D, Thiel E, et al. Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. Leukemia. 2008;22:1154\u201360.","journal-title":"Leukemia"},{"key":"2599_CR98","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1038\/sj.onc.1210185","volume":"26","author":"I Riz","year":"2007","unstructured":"Riz I, Akimov SS, Eaker SS, Baxter KK, Lee HJ, Mari\u00f1o-Ram\u00edrez L, et al. TLX1\/HOX11-induced hematopoietic differentiation blockade. Oncogene. 2007;26:4115\u201323.","journal-title":"Oncogene"},{"key":"2599_CR99","doi-asserted-by":"crossref","unstructured":"Monteiro FA, Miranda RM, Samina MC, Dias AF, Raposo A, Oliveira P, et al. Tlx3 Exerts Direct Control in Specifying Excitatory Over Inhibitory Neurons in the Dorsal Spinal Cord. Front Cell Dev Biol. 2021;9:642697.","DOI":"10.3389\/fcell.2021.642697"},{"key":"2599_CR100","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1007\/s13277-014-1873-5","volume":"35","author":"J Ma","year":"2014","unstructured":"Ma J, Hua J, Sha Y, Xie Y. The effect of TLX3 expression on the prognosis of pediatric T cell acute lymphocytic leukemia\u2014a systematic review. Tumor Biol. 2014;35:8439\u201343.","journal-title":"Tumor Biol"},{"key":"2599_CR101","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020010081","volume":"138","author":"GP Andrieu","year":"2021","unstructured":"Andrieu GP, Kohn M, Simonin M, Smith CL, Cieslak A, Dourthe M-\u00c9, et al. PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. Blood. 2021;138:1855\u201369.","journal-title":"Blood"},{"key":"2599_CR102","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/ng.587","volume":"42","author":"M Kleppe","year":"2010","unstructured":"Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nature Genet. 2010;42:530\u20135.","journal-title":"Nature Genet"},{"key":"2599_CR103","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1078-0432.CCR-23-2159","volume":"30","author":"A Pinton","year":"2024","unstructured":"Pinton A, Courtois L, Doublet C, Cabannes-Hamy A, Andrieu G, Smith C, et al. PHF6-altered T-ALL harbor epigenetic repressive switch at bivalent promoters and respond to 5-azacitidine and venetoclax. Clinical Cancer Res. 2024;30:94\u2013105.","journal-title":"Clinical Cancer Res"},{"key":"2599_CR104","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2007-04-079988","volume":"110","author":"J Bergeron","year":"2007","unstructured":"Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, et al. Prognostic and oncogenic relevance of TLX1\/HOX11 expression level in T-ALLs. Blood. 2007;110:2324\u201330.","journal-title":"Blood"},{"key":"2599_CR105","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2141.2009.07944.x","volume":"148","author":"A Attarbaschi","year":"2010","unstructured":"Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, et al. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin\u2013Frankfurt\u2013M\u00fcnster (BFM) protocols containing early and late re-intensification elements. British J Haematol. 2010;148:293\u2013300.","journal-title":"British J Haematol"},{"key":"2599_CR106","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3324\/haematol.13291","volume":"93","author":"B Paola","year":"2008","unstructured":"Paola B, Judith L-P, Jean Michel C, Vahid A, Myriam L, Virginie G, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3\/HOX11L2 gene expression on outcome. Haematologica. 2008;93:1658\u201365.","journal-title":"Haematologica"},{"key":"2599_CR107","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/s41416-023-02216-y","volume":"128","author":"E Heylen","year":"2023","unstructured":"Heylen E, Verstraete P, Van Aerschot L, Geeraerts SL, Venken T, Timcheva K, et al. Transcription factor NKX2\u20131 drives serine and glycine synthesis addiction in cancer. British J Cancer. 2023;128:1862\u201378.","journal-title":"British J Cancer"},{"key":"2599_CR108","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/gcc.22887","volume":"59","author":"MO Forgione","year":"2020","unstructured":"Forgione MO, McClure BJ, Yeung DT, Eadie LN, White DL. MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies. Genes, Chromosomes Cancer. 2020;59:709\u201321.","journal-title":"Genes, Chromosomes Cancer"},{"key":"2599_CR109","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V122.21.5022.5022","volume":"122","author":"K Matlawska-Wasowska","year":"2013","unstructured":"Matlawska-Wasowska K, Harvey RC, Heerema NA, Carroll AJ, Devidas M, Loh ML, et al. AF10 Fusion Transcripts Are Identified By HOXA9\/10 and MEIS1 Overexpression In T-ALL: A Report From Children\u2019s Oncology Group AALL0434. Blood. 2013;122:2601.","journal-title":"Blood"},{"key":"2599_CR110","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood-2002-09-2913","volume":"102","author":"V Asnafi","year":"2003","unstructured":"Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCR\u03b3\u03b4 lineage. Blood. 2003;102:1000\u20136.","journal-title":"Blood"},{"key":"2599_CR111","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1002\/j.1460-2075.1990.tb07535.x","volume":"9","author":"L Brown","year":"1990","unstructured":"Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G, et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 1990;9:3343\u201351.","journal-title":"EMBO J"},{"key":"2599_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78629-z","volume":"10","author":"A Meyer","year":"2020","unstructured":"Meyer A, Herkt S, Kunze-Schumacher H, Kohrs N, Ringleb J, Schneider L, et al. The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis. Scientific Rep. 2020;10:21438.","journal-title":"Scientific Rep"},{"key":"2599_CR113","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1080\/10428190903040014","volume":"50","author":"MB Mansur","year":"2009","unstructured":"Mansur MB, Emerenciano M, Brewer L, Sant\u2019ana M, Mendon\u00e7a N, LCs Thuler, et al. SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leukemia Lymphoma. 2009;50:1318\u201325.","journal-title":"Leukemia Lymphoma"},{"key":"2599_CR114","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3324\/haematol.2014.112151","volume":"100","author":"DA Mariella","year":"2015","unstructured":"Mariella DA, Maria GV, Anna MT, Valentino C, Vittorio N, Rosanna P, et al. Clinical features and outcome of SIL\/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. Haematologica. 2015;100:e10\u2013e3.","journal-title":"Haematologica"},{"key":"2599_CR115","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","volume":"346","author":"MR Mansour","year":"2014","unstructured":"Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346:1373\u20137.","journal-title":"Science"},{"key":"2599_CR116","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/blood-2004-09-3666","volume":"105","author":"V Asnafi","year":"2005","unstructured":"Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron J-M, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005;105:3072\u20138.","journal-title":"Blood"},{"key":"2599_CR117","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2012-09-458570","volume":"122","author":"MP McCormack","year":"2013","unstructured":"McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, et al. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood. 2013;122:2093\u2013103.","journal-title":"Blood"},{"key":"2599_CR118","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11033-013-2952-1","volume":"41","author":"M Sang","year":"2014","unstructured":"Sang M, Ma L, Sang M, Zhou X, Gao W, Geng C. LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins. Molecular Biol Rep. 2014;41:1067\u201373.","journal-title":"Molecular Biol Rep"},{"key":"2599_CR119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0092-8674(94)90571-1","volume":"78","author":"AJ Warren","year":"1994","unstructured":"Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78:45\u201357.","journal-title":"Cell"},{"key":"2599_CR120","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/2159-8290.CD-23-1452","volume":"14","author":"S Kimura","year":"2024","unstructured":"Kimura S, Park CS, Montefiori LE, Iacobucci I, P\u00f6l\u00f6nen P, Gao Q, et al. Biologic and clinical analysis of childhood gamma delta T-ALL Identifies LMO2\/STAG2 Rearrangements as Extremely High Risk. Cancer Discov. 2024;14:1838\u201359.","journal-title":"Cancer Discov"},{"key":"2599_CR121","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/leu.2011.119","volume":"25","author":"S Chen","year":"2011","unstructured":"Chen S, Nagel S, Schneider B, Kaufmann M, Meyer C, Zaborski M, et al. Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2. Leukemia. 2011;25:1632\u20135.","journal-title":"Leukemia"},{"key":"2599_CR122","doi-asserted-by":"crossref","unstructured":"Harrison DA. The Jak\/STAT pathway. Cold Spring Harb Perspect Biol. 2012;4:a011205.","DOI":"10.1101\/cshperspect.a011205"},{"key":"2599_CR123","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1097\/HS9.0000000000000313","volume":"3","author":"I Govaerts","year":"2019","unstructured":"Govaerts I, Jacobs K, Vandepoel R, Cools J. JAK\/STAT pathway mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1\/JAK3 Inhibitors. HemaSphere. 2019;3:e313.","journal-title":"HemaSphere"},{"key":"2599_CR124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"L Courtois","year":"2023","unstructured":"Courtois L, Cabannes-Hamy A, Kim R, Delecourt M, Pinton A, Charbonnier G, et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition. Blood. 2023;142:158\u201371.","journal-title":"Blood"},{"key":"2599_CR125","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK Inhibitors. Pharmaceutics. 2022;14:1001.","journal-title":"Pharmaceutics"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02599-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:03:20Z","timestamp":1748937800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02599-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02599-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.Y. receives research support from BMS & Novartis, and Honoraria from Novartis, Pfizer, Ascentage and AMGEN. D.L.W. receives research support from BMS and Honoraria from BMS and AMGEN. All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}